Real-World Open-Label Experience with Rimegepant for the Acute Treatment of Migraine Attacks: A Multicenter Pilot Study

Real-World Open-Label Experience with Rimegepant for the Acute Treatment of Migraine Attacks: A Multicenter Pilot Study

<b>Objectives:</b> The present open-label multicenter pilot study sought to prospectively evaluate the efficacy and safety of rimegepant in treating migraine attacks. <b>Methods:</b> The primary endpoint was pain freedom at two hours post-dose, while the co-primary efficacy e...

Full description

Saved in:
Bibliographic Details
Main Authors: Emmanouil V. Dermitzakis, Dimitrios Rikos, Michail Vikelis, Georgia Xiromerisiou, Styliani Zisopoulou, Dimitrios Rallis, Panagiotis Soldatos, George S. Vlachos, Georgios G. Vasiliadis, Andreas A. Argyriou
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Brain Sciences
Subjects:
migraine
acute treatment
gepants
rimegepant
Online Access:https://www.mdpi.com/2076-3425/14/12/1169
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2076-3425/14/12/1169

Similar Items